Allogene Therapeutics Inc
NASDAQ:ALLO
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Allogene Therapeutics Inc
Allogene Therapeutics Inc
Net Issuance of Common Stock
Allogene Therapeutics Inc
Net Issuance of Common Stock Peer Comparison
ABBV
GILD
AMGN
VRTX
REGN
Competitive Net Issuance of Common Stock Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Allogene Therapeutics Inc
NASDAQ:ALLO
|
Net Issuance of Common Stock
$95.6m
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Issuance of Common Stock
-$1.1B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
37%
|
CAGR 10-Years
-18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Issuance of Common Stock
-$719m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
22%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Issuance of Common Stock
-$288.7m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Issuance of Common Stock
-$473.2m
|
CAGR 3-Years
51%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Allogene Therapeutics Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
95.6m
USD
Based on the financial report for Mar 31, 2024, Allogene Therapeutics Inc's Net Issuance of Common Stock amounts to 95.6m USD.
What is Allogene Therapeutics Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 5Y
-32%
Over the last year, the Net Issuance of Common Stock growth was 3 232%. The average annual Net Issuance of Common Stock growth rates for Allogene Therapeutics Inc have been -46% over the past three years , -32% over the past five years .
You don't have any saved screeners yet
